Elevance Health Raises Earnings Outlook on Higher 2Q Sales

Dow Jones
07/15
 

Elevance Health raised its earnings outlook after logging a higher benefit-expense ratio and sales number in the second quarter.

The health insurer on Wednesday posted a profit of $1.46 billion, or $6.71 a share, compared with $1.74 billion, or $7.72 a share, a year earlier.

Stripping out one-time items, adjusted earnings were $7.45 a share. Analysts polled by FactSet had expected $6.21 a share.

Revenue rose 3% to $50.47 billion, compared with estimates of $48.84 billion that Wall Street modeled.

The benefit-expense ratio, a closely watched metric that compares health costs with premium revenue, rose to 89.7% from 88.9%.

The company attributed the higher benefit-expense ratio primarily to improved performance in individual Affordable Care Act coverage compared with the year before. That was partly offset by an expected increase in medical costs in Elevance's government business.

Medical membership, a tally of enrollees in its insurance plans, slipped by 469,000 sequentially to 44.9 million as of the end of June. The decline was driven by a commercial fee-based customer transition and some membership attrition.

For the year, the Indianapolis company expects adjusted earnings of at least $27 a share. Analysts currently expected adjusted earnings of $26.91 a share, and Elevance had previously guided for $26.75 a share.

The outlook marks a guidance increase by the company. Elevance is also raising its target investments in medical cost management, member experience and provider connectivity.

These updates reinforce management's confidence in meeting its goal to return at least 12% adjusted earnings per share growth in 2027, compared with 2026, Chief Executive Gail Boudreaux said.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

July 15, 2026 06:31 ET (10:31 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10